No abstract

Cyanobacteria are blue-green Gram-negative and photosynthetic bacteria which are seen as one of the most morphologically numerous groups of prokaryotes. Because of their ability to fix gaseous nitrogen and carbon dioxide to organic materials, they are known to play important roles in the universal nutrient cycle. Cyanobacteria has emerged as one of the promising resources to combat the issues of global warming, disease outbreaks, nutrition insecurity, energy crises as well as persistent daily human population increases. Cyanobacteria possess significant levels of macro and micronutrient substances which facilitate the versatile popularity to be utilized as human food and protein supplements in many countries such as Asia. Cyanobacteria has been employed as a complementary dietary constituent of feed for poultry and as vitamin and protein supplement in aquatic lives. They are effectively used to deal with numerous tasks in various fields of biotechnology, such as agricultural (including aquaculture), industrial (food and dairy products), environmental (pollution control), biofuel (bioenergy) and pharmaceutical biotechnology (such as antimicrobial, anti-inflammatory, immunosuppressant, anticoagulant and antitumor); recently, the growing interest of applying them as biocatalysts has been observed as well. Cyanobacteria are known to generate a numerous variety of bioactive compounds. However, the versatile potential applications of cyanobacteria in biotechnology could be their significant growth rate and survival in severe environmental conditions due to their distinct and unique metabolic pathways as well as active defensive mechanisms. In this review, we elaborated on the versatile cyanobacteria applications in different areas of biotechnology. We also emphasized the factors that could impede the implementation to cyanobacteria applications in biotechnology and the execution of strategies to enhance their effective applications.

The evolutional development of the RNA translation process that leads to protein synthesis based on naturally occurring amino acids has its continuation via synthetic biology, the so-called rational bioengineering. Genetic code expansion (GCE) explores beyond the natural translational processes to further enhance the structural properties and augment the functionality of a wide range of proteins. Prokaryotic and eukaryotic ribosomal machinery have been proven to accept engineered tRNAs from orthogonal organisms to efficiently incorporate noncanonical amino acids (ncAAs) with rationally designed side chains. These side chains can be reactive or functional groups, which can be extensively utilized in biochemical, biophysical, and cellular studies. Genetic code extension offers the contingency of introducing more than one ncAA into protein through frameshift suppression, multi-site-specific incorporation of ncAAs, thereby increasing the vast number of possible applications. However, different mediating factors reduce the yield and efficiency of ncAA incorporation into synthetic proteins. In this review, we comment on the recent advancements in genetic code expansion to signify the relevance of systems biology in improving ncAA incorporation efficiency. We discuss the emerging impact of tRNA modifications and metabolism in protein design. We also provide examples of the latest successful accomplishments in synthetic protein therapeutics and show how codon expansion has been employed in various scientific and biotechnological applications.

Globally, there is an increasing report of bacterial resistance to currently available antibiotics. The urgent need for newer therapeutic modalities was the incentive for the current evaluation of bactericidal and inhibitory effects of methanolic and aqueous extracts of Mitracarpus villosus on selected antibiotic resistant Gram-positive and Gram-negative bacteria. Ten-fold serial dilution was used to test the effects of the extracts. The percentage yield of extractable components was 22% for methanol and 8.3% for water. The minimum inhibitory concentration (MIC) of methanolic extract was 0.001 mg/mL against Streptococcus pyogenes, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, and Salmonella Typhi showing resistance to antibiotics and 0.01 mg/mL for Staphylococcus aureus, Bacillus subtilis, and Klebsiella pneumoniae while the minimum bactericidal concentration (MBC) was 0.1 mg/mL for all the isolates except S. aureus and E. coli with MBC of 0.01 mg/mL. Similarly, the MIC of aqueous extract was 0.01 mg/mL for S. pyogenes, S. aureus, B. subtilis, and K. pneumoniae; 0.1 mg/mL against S. faecalis and E. coli; 0.001 mg/mL against P. aeruginosa and S. typhi. The MBC of the aqueous extract at 0.1 mg/mL was active against S. pyogenes, S. faecalis, P. aeruginosa, K. pneumonia, and S. typhi; 1.0 mg/mL was active against S. aureus, B. subtilis, and E. coli. Findings from the present study indicate that the extracts of M. villosus have the potential to be used for treatment and cure of infections caused by selected bacteria. The methanolic extracts show more potent activity. Further study on a larger scale at varied concentrations including a test for potential toxicity in cultured cells are needed to depict their safety profiles before recommendation for inclusion in the antibacterial armamentarium.

No abstract

No abstract